Clinical Trials Logo

Intraocular Lymphoma clinical trials

View clinical trials related to Intraocular Lymphoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05950490 Recruiting - Clinical trials for Primary Vitreoretinal Lymphoma

Construction of Diagnosis and Treatment System for Primary Vitreoretinal Lymphoma

Start date: October 1, 2022
Phase:
Study type: Observational [Patient Registry]

This study intends to apply for the establishment of research beds, establish a Chinese PVRL research cohort, and carry out a to achieve the following research objectives: The goal of this prospective observational study is to construct the diagnosis and treatment system for primary vitreoretinal lymphoma(PVRL). The study is to achieve the following research objectives: 1. To establish a comprehensive diagnostic criteria for PVRL with high diagnostic efficiency and strengthen the PVRL diagnostic system; 2. To establish a standardized treatment pathway for PVRL and evaluate the efficacy and safety of treatment; 3. To screen the prognosis evaluation indicators, and to establish the follow-up process and prognosis evaluation system of PVRL; 4. To explore the pathogenesis of PVRL, specific tumor markers and drug therapeutic targets.

NCT ID: NCT04899453 Recruiting - Clinical trials for Primary Vitreoretinal Lymphoma

Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL

Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective single-arm phase II study, and the purpose of this study is to evaluate the efficiency of ZR regimen (rituximab & Zanubrutinib) combined with intravitreal methotrexate and followed by Zanubrutinib maintenance in newly-diagnosed primary intraocular lymphoma. Progression-free survival (PFS) of the cohort is the primary endpoint.

NCT ID: NCT03746223 Recruiting - Clinical trials for Primary Intraocular Lymphoma

Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma

Start date: November 15, 2018
Phase: Phase 2
Study type: Interventional

This is a prospective single arm phase II study, and the purpose of this study is to evaluate the efficiency of R2 regimen (rituximab & lenalidomide) combined with intravitreal methotrexate and followed by lenalidomide maintenance in newly-diagnosed primary intraocular lymphoma. Progression free survival (PFS) of the cohort is the primary endpoint.